Clinic Follow-Up Interval for Ongoing Lorazepam Prescribing
Patients receiving chronic benzodiazepine therapy (including lorazepam) should have periodic clinic follow-up visits to reassess risks, benefits, and safety monitoring. A risk-stratified minimum follow-up interval of every 6 months for high-risk patients and at least annually for standard-risk patients is recommended in a benzodiazepine safety guideline. [1]
Medication Selection Algorithm
Lorazepam is a benzodiazepine and is managed using chronic benzodiazepine safety monitoring principles. [1]
Core Recommendation (Visit Frequency)
- High-risk chronic benzodiazepine users: provider visit every 6 months minimum, with at least one face-to-face office visit per year. [1]
- Standard-risk chronic benzodiazepine users: provider visit annually, with face-to-face office visit required. [1]
- Patients taking opioids concurrently with benzodiazepines: follow-up visit every 3 months minimum. [1]
Initiation Thresholds for Follow-Up Frequency
Follow-up intensity should be determined by benzodiazepine risk stratification categories for chronic use, rather than by lorazepam dose alone. [1]
Risk-Based Criteria Driving More Frequent Follow-Up
High-risk criteria include (non-exhaustive): [1]
- Age ≥65. [1]
- Age <25. [1]
- More than 1 benzodiazepine prescription. [1]
- Benzodiazepine plus Z-drug combination. [1]
- Benzodiazepine plus opioid combination. [1]
- History of substance use disorder. [1]
- Use of alcohol or cannabis. [1]
- COPD or severe/uncontrolled respiratory disease or risk of respiratory depression. [1]
- History of overdose. [1]
- Fall risk or problems following a benzodiazepine care plan. [1]
Common Pitfalls to Avoid
- Allowing benzodiazepine prescribing to continue without risk-based scheduled reassessment visits for chronic therapy. [1]
- Under-scheduling follow-up for patients at high risk or for those concurrently using opioids. [1]
Safety Monitoring Usually Paired With Follow-Up
Benzodiazepine follow-up visits should include prescription monitoring review at each visit and appropriate safety screening and documentation elements as specified by the guideline. [1]
Targets or Goals of Therapy
The goal of ongoing visits is to reassess continued need for chronic benzodiazepine therapy and mitigate sedative harms through scheduled risk-based monitoring. [1]